A novel identified circular RNA, circ_0000491, aggravates the extracellular matrix of diabetic nephropathy glomerular mesangial cells through suppressing miR-101b by targeting TGFβRI

Abstract

Circular RNAs (circRNAs) have crucial roles in various diseases; however, the mechanisms of action underlying circRNAs in the occurrence and development of diabetic nephropathy (DN) remains largely unknown. The present study investigated the differentially expressed circRNAs in the DN mice kidney cortex using circRNA sequencing and elucidated the role of circRNAs in mesangial cells. It was revealed that 40 circRNAs were unconventionally expressed, including 18 upregulated circRNAs and 22 downregulated circRNAs. Furthermore, circ_0000491 levels were significantly augmented in both DN mice and high glucose (HG, 30 mM)-induced mouse mesangial cells (MES13 cells). Knockdown of circ_0000491 significantly suppressed the increase of vimentin, fibronectin and α-smooth muscle actin, as well as collagen type I, III and IV, whilst reversing the decrease of E-cadherin in HG-induced MES13 cells. It was further revealed that circRNA_0000491 sponged miR-101b and that miR-101b directly targets TGFβRI. In addition, the expression levels of miR-101b were negatively associated with the transcriptional level of circRNA_0000491 and miR-101b inhibitors reversed the suppression of extracellular matrix (ECM)-associated protein synthesis mediated by knocking-down circRNA_0000491. In conclusion, the present study investigated the circRNA_0000491/miR-101b/TGFβRI axis in ECM accumulation and fibrosis-associated protein expression levels of mesangial cells, which suggested that circRNA_0000491 may be beneficial for the development of an effective therapeutic target for DN.

Introduction

Diabetic nephropathy (DN) is becoming the most pervasive complication for both types I and II diabetes, and is also the major cause of end-stage renal disease in the majority of developed and developing countries (1). Clinically, DN is characterized by mesangial hypertrophy, mesangial cell (MC) proliferation, albuminuria, extracellular matrix (ECM) accumulation and kidney fibrosis (2,3). It has been recognized that the glomerular MCs and ECM accumulation are involved in a variety of biological events (4). A recent study suggested that high concentration glucose-induced MCs contribute to the initiation and development of kidney fibrosis with an elevated level of fibroin and cytokines expression (5). Thus, it is of utmost importance to investigate the key targets and mechanisms of action underlying the action of MCs in high glucose for the treatment and prevention strategies of DN.

Studies have also begun to demonstrate the participation and regulatory mechanism of non-coding RNAs (ncRNAs) on DN development (6,7). Circular RNAs (circRNAs) are a novel class of endogenous ncRNAs, which mediate diverse physiological and pathological changes in the human body (8), including DN, and are characterized by a covalently-closed loop formed by back-splicing between the 5′ to 3′ ends of the polyA tail (9,10). Initially, circRNAs were incorrectly recognized as splicing errors without any biological functions. There is an increasing evidence indicating that some circRNAs play a significant role in regulating various human diseases through a competing endogenous RNA (ceRNA) mechanism, also known as a micro (mi)RNA sponge (5,11). For example, Li et al (12) revealed that overexpression of circRNA circ-0001785 promotes the proliferative ability of osteosarcoma cells, acting as a ceRNA by sponging miR-1200 to upregulate HOXB2. circ homeodomain interacting protein kinase 3 (HIPK3) is upregulated in Ang II-induced cardiac fibroblasts (CFs) and heart tissues, promoting the proliferation and migration of CFs by acting as a miR-29b-3p sponge (13), suggesting that circRNAs may accelerate the development of fibrosis by acting as an miRNA sponge. Additionally, Chen et al (1) have shown that the circ LDL receptor related protein 6 (LRP6) acts as a ‘sponge’ of miR-205 to promote ECM-related protein synthesis in MCs by upregulating high mobility group box 1 (HMGB1) and activating Toll-like receptor 4 (TLR4)/NF-κB pathway. Similarly, a study by Hu et al (5) found that the circRNA_15698 /miR-185/TGF-β1 signaling pathway promoted ECM accumulation in DN MCs. Although advances have been made into the roles of circRNAs in human diseases, the role of more novel circRNAs on ECM accumulation and fibrosis-associated proteins, as well as the detailed mechanisms of actions that circRNAs play in MCs remains unclear.

The present study demonstrated a high expression level of mmu_circRNA_0000491 (chr13:94111710-94126034) in mice with DN, as well as the MCs that received high concentration glucose treatment. In addition, the present study also investigated the involvement of the circRNA_0000491/miR-101b/TGFβ-receptor type I (TGFβRI) axis on the ECM of DN tissue. It was hypothesized that circRNA_0000491 worsens the accumulation of ECM of MCs through negatively suppressing miR-101b by targeting TGFβRI.

Materials and methods

Animals

A total of three six-week-old spontaneous male diabetic db/db mice (weight: ~18.3–20 g) and three age-matched control littermate db/m mice (weight: ~17.6–21.4 g) were obtained from the Shanghai SLAC Laboratory Animal Co., Ltd. All mice were housed in a pathogen-free facility under a controlled temperature of 22±1°C, 60±5% humidity and a 12-h light and dark cycle, with free access to water and a regular standard diet. All the procedures were approved by the Animal Care and Welfare Committee of Zhejiang Chinese Medical University (approval no. ZSLL-2018-192).

circRNA sequencing

The db/m control and db/db mice were euthanized by cervical dislocation, then the kidney cortex from the renal tissues was isolated. Subsequently, total RNA was extracted from the kidney cortex using TRIzol^® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and RNA purity, concentration and integrity were measured using a NanoPhotometer^® spectrophotometer (IMPLEN), a Qubit^® RNA assay kit in the Qubit^® 2.0 Flurometer (Thermo Fisher Scientific, Inc.) and an RNA Nano 6000 Assay kit in the Bioanalyzer 2100 system (Agilent Technologies, Inc.), respectively. circRNA microarray analysis was performed by Novogene Co., Ltd. Briefly, a total of 5 µg RNA per sample was applied as input material for the RNA sample preparations. Firstly, ribosomal (r)RNA was removed using the Epicentre Ribo-zero™ rRNA Removal kit (Epicentre; Illumina, Inc.) and rRNA free residue was cleaned up by ethanol precipitation. Subsequently, the linear RNA was digested with 3 units of RNase R (Epicentre; Illumina, Inc.) per µg of RNA. The sequencing libraries were generated with a NEBNext^® Ultra™ Directional RNA Library Prep kit for Illumina^® (New England BioLabs, Inc.) according to the manufacturer's protocol. circRNA was detected and identified using find_circ (14) and CIRI2 (15). The differentially expressed circRNAs were identified by utilizing the edgeR R package (v3.31.4; http://bioconductor.org) in R (v3.6.1; http://www.r-project.org/) with the threshold set at a P<0.01 and |log2(fold change)|>1. To investigate the underlying function of candidate circRNAs, UCSC Genome Browser (http://genome.ucsc.edu/) was used to illustrate their composition (16).

Cell culture and transfection

MES13 cells from a SV40 transgenic mouse (SV40 MES13) were acquired from the Shanghai Academy of Life Sciences, and maintained in DMEM (Sigma-Aldrich; Merck KGaA) supplemented with 10% FBS (Thermo Fisher Scientific, Inc.) and 1% penicillin and streptomycin (Welgene Inc.) in a 37°C incubator with 5% CO₂. MES13 cells were stimulated with 5.5 mM D-glucose for the control group. For the model group, the MES13 cells were stimulated with 30 mM glucose for 48 h in order to simulate the condition of the DN cells. In addition, small interfering RNAs (siRNAs), scrambled siRNA (si_Circ_Control), miR-101b mimics/inhibitor and negative controls, used for cell transfections, were purchased from RiboBio Co., Ltd. The sequences used were as follows: CircRNA_0000491 si_Circ_1, 5′-ATATGGACCAAGAATACCAAA−3′; circRNA_0000491 si_Circ-2, 5′-TATATGGACCAAGAATACCAA−3′; si_Circ_Control, 5′-TTCTCCGAACGTGTCACGTTT−3′; miR-101b mimic, 5′-GUACAGUACUGUGAUAGCU-3′; miR-101b inhibitor, 5′-AGCUAUCACAGUACUGUAC-3′. All the specialized siRNAs were transfected into MES13 cells using Lipofectamine^® 3000 (Gibco; Thermo Fisher Scientific, Inc.). The subsequent experiments were performed in MES13 cells following 48 h transfection.

Reverse transcription-quantitative (RT-q) PCR

Total RNA was obtained from kidney samples and MES13 cells using TRIzol^® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and reverse transcribed into cDNA using a PrimeScript RT reagent kit (Takara Bio, Inc.). The reverse transcription conditions were 37°C for 15 min, and reverse transcriptase inactivation at 85°C for 5 sec. For miRNA quantification, cDNA synthesis was performed using the Mir-X™ miRNA First-Strand Synthesis kit (Clontech Laboratories, Inc.). Subsequently, qPCR was performed using a CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) with the amplification conditions: Pre-denaturation at 95°C for 30 sec, followed by 40 cycles of denaturation at 95°C for 5 sec and annealing at 60°C for 30 sec. The dissolution curve conditions were 65°C for 0.05 sec and 95°C for 0.5 sec. The primers used for RT-qPCR were as follows: mmu_circ_0000491 forward, 5′-TCGGCTTGCAAAGGAGAAGTC−3′ and reverse, 5′-TGCATGCTTGCTGGTGGGTA-3′; E-cadherin (E-cad) forward, 5′-CTCAAGCTCGCGGATAACCA-3′ and reverse, 5′-AATCCTGCTGCCACGATTC-3′; vimentin (Vim) forward, 5′-TGTGACAACTGCCGTAGACC-3′ and reverse, 5′-TAGCGGCATGAAGCACTCAA-3′; Fibronectin (FN) forward, 5′-AAGAAGGGCTCGTGTGACAG-3′ and reverse, 5′-GGAAGGGTTACCAGTTGGGG-3′; α-SMA forward, 5′-AAGAGAGGGATCCTGACGCT-3′ and reverse, 5′-CTCCAGGGAGGAAGAGGAGG-3′; Type I collagen (Col. I) forward, 5′-CGTATCACCAAACTCAGAAGATGT−3′, and reverse, 5′-AGAGCCTCTAGCTCCTTGGG-3′; Type III collagen (Col. III) forward, 5′-ATGCCCACAGCCTTCTACAC-3′ and reverse, 5′-GGGTCACCATTTCTCCCAGG-3′; Type IV collagen (Col. IV) forward, 5′-GGTGTTCCAGGAAGAGGCTT-3′ and reverse, 5′-CATGCCTTGGAATCCTGGGT-3′; TGFβRI forward, 5′-AGCTCCTCATCGTGTTGGTG-3′ and reverse, 5′-AAACCGACCTTTGCCAATGC-3′; miR-101b forward, 5′-GGGCTACTGTGATAGCTAAAA−3′; and 5′-CCAGTGCAGGGTCCGAGGTA-3′, as the reverse. In addition, the transcriptional levels of mmu_circ_0000712, mmu_circ_0000898, novel_circ_0001857 and novel_circ_0001778 were estimated in the kidney samples of db/db mice. The sequences and primers of mmu_circ_0000712, mmu_circ_0000898, novel_circ_0001857 and novel_circ_0001778 are shown in Tables SI and SII. GAPDH was used as internal control for the circRNA and mRNA. U6 acted as an internal standard of miR-101b. Relative quantification of expression was performed compared with internal standard with the 2^−ΔΔCq method (17).

Western blotting

Total cellular protein samples were acquired at 4°C in RIPA buffer (Sigma-Aldrich; Merck KGaA), then the protein concentration was estimated using a BCA kit (Beyotime Institute of Biotechnology). Proteins (40 µg) were separated by SDS-PAGE (10–12% gel) and transferred onto polyvinylidene fluoride membranes (GE Healthcare). The membranes were blocked with 5% skim milk powder for 2 h at room temperature, and incubated overnight at 4°C with primary antibodies against E-cadherin (1:1,000, cat. no. 14472, Cell Signaling Technology, Inc.), vimentin (1:1,000, cat. no. 5741, Cell Signaling Technology, Inc.), FN (1:1,000, ab268020, Abcam), α-SMA (1:1,000, cat. no. 68463, Cell Signaling Technology, Inc.), Type I collagen (1:1,000, cat. no. 39952, Cell Signaling Technology, Inc.), Type III collagen (1:1,000, ab184993, Abcam), Type IV collagen (1:1,000, cat. no. 50273, Cell Signaling Technology, Inc.), TGFβ1 (1:1,000, sc-130348, Santa Cruz Biotechnology, Inc.), TGFβR1 (1:2,000, ab31013, Abcam), phosphorylated (p-)Smad3 (1:2,000, ab52903, Abcam), and Smad3 (1:2,000, ab40854, Abcam), with GAPDH serving as an internal control (1:1,000, D190090-0200, Sangon Biotech Co., Ltd.). After exposure to horseradish peroxidase (HRP)-labeled goat anti-rabbit (cat. no. A24531, 1:5,000, Invitrogen; Thermo Fisher Scientific, Inc.) or goat anti-mouse secondary antibodies (cat. no. 31432, 1:5,000, Invitrogen; Thermo Fisher Scientific, Inc.) at room temperature for 2 h, the bands were visualized with enhanced chemiluminescence (Beyotime Institute of Biotechnology) and analyzed using an Odyssey^® IR scanner (LI-COR Biosciences).

Luciferase reporter assay

Using the starBase v3.0 database (http://starbase.sysu.edu.cn/index.php), the interactions between circ_0000491 and miR-101b were confirmed. starBase is an open-source platform for studying the miRNA-ncRNA interactions from CLIP-seq, degradome-seq and RNA-RNA interactome data (18). In addition, the mRNAs targeted by miR-101b were retrieved from the TargetScan (version 7.2, http://www.targetscan.org/vert_72/) (19), miRDB (http://mirdb.org/) (20) and PicTar(https://pictar.mdc-berlin.de/) databases. Then, the luciferase reporter assay was applied in MES13 cells. Briefly, MES13 cells were plated into 24-well plates at 60% confluence. circ_0000491/TGFβRI reporter construct (mutant or wild-type) or the empty reporter vector psiCHECK-2 (Promega Corporation) was co-transfected with miR-101b mimics or control mimics using Lipofectamine^® 3000 (Thermo Fisher Scientific, Inc.). After 48 h of transfection, the luciferase activity was measured with a Dual-Luciferase Reporter Assay System (Promega Corporation) according to the manufacturer's protocol. The relative reporter activity was normalized to the ratio of firefly luciferase to Renilla luciferase.

Statistical analysis

All data are presented as the mean ± SD. Student's unpaired t-tests (two tailed) were used for comparisons between two groups. The statistical difference of the luciferase reporter assay was evaluated using a one-way ANOVA followed by Tukey's post-hoc tests. Statistical analysis was performed using SPSS 20.0 (IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

Results

circRNA expression profile analysis in DN mice

In order to investigate the differentially expressed circRNAs in the kidney tissue, the present study employed mouse circRNA sequencing in db/m and db/db mice with DN. Heat maps (Fig. 1A) and volcano plots (Fig. 1B) revealed that a total of 40 circRNAs, including 18 upregulated circRNAs and 22 downregulated circRNAs, were differentially expressed, using P<0.01 and |log2(fold change)|>1 as a significant cut off criterion.

Figure 1.

circRNA microarray analysis and circRNA_0000491 are upregulated in db/db diabetic nephropathy mice kidney tissues and MES13 cells treated with high glucose. (A) Heat maps and (B) volcano plots displaying the differentially expressed circRNAs. (C) A schematic diagram of the genomic location and structure of circ_0000491. circRNA, circular RNA.

Overexpression of circRNA_0000491 in kidney tissue and high glucose-treated mouse MES13 cells

RT-qPCR was used to evaluate mmu_circ_0000712, mmu_circ_0000898, novel_circ_0001857, circRNA_0000491 and novel_circ_0001778 levels in 3 paired kidney tissue samples (Fig. S1). It was found that the transcriptional levels of mmu_circ_0000712, novel_circ_0001857 and novel_circ_0001778 were significantly increased in the kidney tissue of db/db mice. Furthermore, according to the UCSC Genome Browser, mmu_circ_0000491 is produced at the Homer1 gene locus, containing exons 2–5 (Fig. 1C). The results also revealed that circRNA_0000491 expression was markedly amplified in the db/db mice (Fig. 2A). Among the upregulated circRNAs, it was noted that circRNA_0000491 was significantly increased; therefore, this circRNA was selected for further experiments. Additionally, it was observed that circ_0000491 expression was markedly upregulated in MES13 cells exposed to high glucose for 12 and 24 h, respectively, when compared with the expression in control cells (Fig. 2B). These findings documented the high expression levels of circRNA_0000491 in db/db mouse kidney tissue.

Figure 2.

Expression of circRNA_0000491 in the kidney tissue of db/db mice and high glucose-induced mouse MES13 cells. (A) Reverse transcription-quantitative PCR estimated the expression levels of circ_0000491 in diabetic nephropathy mice and (B) the high concentration glucose (30 mM)-induced MES13 cells. ^##P<0.01 vs. the db/m control group; **P<0.01 vs. the 5.5 mM glucose treated MES13 cells group. circRNA, circular RNA.

Knockdown of circRNA_0000491 suppresses ECM accumulation of MES13 cells

circRNA microarray analyses identified a variety of dysregulated circRNAs in the DN mouse kidney cortex (Fig. 1A). Subsequently, the present study identified that circRNA_0000491 was expressed at significantly higher levels in the kidney tissues of the db/db mice and it was speculated that circRNA_0000491 participated in the pathological process of ECM accumulation and renal fibrosis. In the present study, ECM accumulation and fibrosis-associated proteins levels, including E-cad, Vim, FN and α-SMA, as well as Col. Types I, III and IV were investigated using RT-qPCR. The results suggested that the mRNA expression levels of Vim, FN, α-SMA, Col. I, III and IV were increased, while the levels of E-cad were markedly decreased compared with control db/m mice and normal glucose treated MES13 cells (Fig. 3A and B). The role of circRNA_0000491 was further investigated in MES13 cells using a specific siRNA. The knockdown efficiency of si_Circ_1 and si_Circ_2 in MES13 cells was determined by RT-qPCR analysis. The results showed that the expression levels of circRNA_0000491 were significantly decreased in the si_Circ_1 group compared with that in the si_Circ_Control group. Subsequently, the present study selected si_Circ_1 as it had a more effective knockdown efficiency than si_Circ_2 for subsequent experiments (Fig. 3C). Moreover, the western blot analysis revealed that the Vim, FN, α-SMA, Col. I, III and IV protein expression levels were suppressed and that the expression of E-cad in the si_Circ_1 treated group was observably increased compared with the si_Circ_NC group in HG-treated MES13 cells (Fig. 3D-K). Taken together, these findings confirmed that circRNA_0000491 knockdown suppressed the epithelial-to-mesenchymal transition (EMT) process and fibrosis-associated protein synthesis in MES13 cells.

Figure 3.

Circ_0000491 silencing inhibits the extracellular matrix accumulation and fibrosis-associated protein synthesis in MES13 cells. RT-qPCR revealed the expression levels of E-cad, Vim, FN, α-SMA, Col. I, Col. III and Col. IV in (A) diabetic nephropathy mice and (B) MES13 cells treated with high glucose. (C) The expression levels of circ_0000491 in MES13 cells transfected using siRNA. (D) Western blotting showing the protein expression levels of (E) E-cad, (F) Vim, (G) FN, (H) α-SMA, (I) Col. I, (J) Col. III and (K) Col. IV in MES13 cells with high glucose treatment and transfected with si_circ_0000491. *P<0.05, **P<0.01 vs. the corresponding control group; ^#P<0.05, ^##P<0.01 vs. the Si_Circ_NC group. Col., collagen; circRNA, circular RNA; E-cad, E-cadherin; FN, fibronectin; si, small interfering; SMA, smooth muscle actin; Vim, vimentin.

circRNA_0000491 sponges miR-101b in MES13 cells

In the present study, MES13 cells were transfected with miR-101b mimics or miR-101b inhibitor to achieve miR-101b expression, as illustrated in Fig. 4A. The expression of circRNA_0000491 was negatively regulated by miR-101b (Fig. 4B). The suggestion that miR-101b may be sponged by circRNA_0000491 was predicted using the starBase v3.0 platform and the seeding sequences of circ_0000491 and miR-101b are presented in Fig. 4C. In order to validate whether miR-101b is the direct target of circ_0000491, a luciferase reporter assay was performed in the present study. The results revealed that miR-101b mimics significantly inhibited the luciferase activity mediated by wild-type circ_0000491-luciferase reporter, which suggested an interaction between circ_0000491 and miR-101b (Fig. 4D). In addition, the results demonstrated that miR-101b expression was significantly downregulated in DN mice and the high concentration glucose-treated group (Fig. 4E) in comparison to the control groups. Furthermore, miRNA-101b expression was significantly increased in MES13 cells transfected with si_Circ_1 (Fig. 4F). These data suggested that circ_0000491 negatively regulates miR-101b expression by directly sponging miR-101b.

Figure 4.

Circ_0000491 targets miRNA-101b. (A) The miR-101b mRNA expression levels in MES13 cells transfected with miR-101b mimics or miR-101b inhibitor was confirmed using RT-qPCR. (B) Circ_0000491 expression was examined in the transfected MES13 cells. (C) Diagram of the miR-101b putative binding sites in circ_0000491. (D) miR-101b expression in db/db mice and high glucose treated MES13 cells was measured using RT-qPCR. (E) Luciferase reporter assay showed the binding activity of miR-101b and circRNA_0000491. (F) miR-101b mRNA expression levels in MES13 cells transfected with si_circ_0000491 was measured using RT-qPCR. *P<0.05, **P<0.01 vs. the corresponding control group. circRNA, circular RNA; miR/miRNA, microRNA; RT-qPCR, reverse transcription-quantitative PCR; si, small interfering.

miR-101b sponges TGFβRI in MES13 cells

After confirming that circ_0000491 sponges miR-101b in MES13 cells, it was necessary to further determine the downstream target of the circRNA_0000491/miR-101b axis. According to the prediction of the TargetScan, miRDB and PicTar databases, TGFβRI may be a potential downstream target for miR-101b. The underlying complementary binding sequence is presented in Fig. 5A. To further investigate the association between miR-101b and TGFβRI, a luciferase reporter assay was performed. It was found that the luciferase activity was significantly downregulated in wild-type TGFβRI cells co-transfected with miR-101b mimics (Fig. 5B). Furthermore, RT-qPCR revealed that the mRNA expression levels of TGFβRI were markedly increased in DN mice and high glucose-treated MES13 cells compared with the corresponding control groups (Fig. 5C and D). These data verified that TGFβRI servers as the target of miR-101b.

Figure 5.

miRNA-101b targets TGFβRI. (A) Diagram of the binding sites between TGFβRI and miRNA-101b. Red text represents the mutant sequence of TGFβRI (B) Relative luciferase activity of the wild-type and 3′-untranslated region mutant constructs of TGFβRI co-transfected with miR-101b mimics and miRNA control. (C) The mRNA expression levels of TGFβRI in db/db mice. (D) The mRNA expression levels of TGFβRI in the high glucose treated MES13 cells. **P<0.01 Control mimics + wild-type TGFβRI group vs. miR-101b mimics + wild-type TGFβ RI group; ▲P<0.05 db/db group vs. Db/dm group; ^##P<0.01 5.5 mM glucose treated group vs. 30 mM glucose treated group. miR/miRNA, microRNA; TGFβR1, TGFβ receptor 1.

miR-101b rescues the effects of circ_0000491 in MES13 cells by targeting TGFβRI

It was hypothesized that the miR-101b/TGFβRI axis is one-way and that circ_0000491 promotes ECM accumulation and fibrosis in DN cells. To test this hypothesis, the present study performed rescue experiments in which circ_0000491-knockdown cultures underwent transfection with an miR-101b inhibitor and scrambled control. Western blotting revealed that the protein expression of TGFβ1, TGFβRI, phosphorylated (p)Smad3, Vim, FN and α-SMA, as well as Col. I, III and IV were all increased; however, E-cad decreased in the miR-101b inhibitor transfected cells. In addition, the cotransfection of miR-101 inhibitor and si_Circ_1 reversed the effect of circ_0000491 silencing (Fig. 6A-K). Collectively, these results suggested that circ_0000491 acts as a sponge of miR-101b, regulating high glucose-induced ECM accumulation and the expression levels of fibrosis-associated proteins in MCs by upregulating TGFβRI and suppressing miR-101b.

Figure 6.

Effect of circ_0000491 and miRNA-101b inhibition on extracellular matrix and fibrosis-associated protein expression via targeting TGFβRI. (A) Western blotting showed that miR-101b inhibitor reversed the effect of si_circRNA_0000491 on the protein expression levels of (B) TGFβ1, (C) TGFβRI, (D) pSmad3/Smad3, (E) E-cad, (F) Vim, (G) FN, (H) α-SMA, (I) Col. I, (J) Col. III and (K) Col. IV. *P<0.05, **P<0.01. Col., collagen; circRNA, circular RNA; E-cad, E-cadherin; FN, fibronectin; miR/miRNA, microRNA; p, phosphorylated; si, small interfering; SMA, smooth muscle actin; TGFβR1, TGFβ receptor 1; Vim, vimentin.

Discussion

DN is one of the major devastating complications of diabetes mellitus (DM). Notably, 2 in every 10 patients with either type 1 or type 2 DM, will develop DN after 10–20 years (21). The number of patients with DN was 382 million in 2013 and is estimated to reach 592 million by 2035 (22). It is evident that abundant circRNAs exist in the eukaryotic transcriptomes and accumulating evidence suggests that they may have a vital role in regulating a series of human diseases and cellular functions (23). circRNAs are closed RNA transcripts that are conserved among different biological systems. However, to the best of our knowledge, the role of circRNA in DN and the mechanisms of action by which circRNAs regulate the accumulation of the ECM and fibrosis has not been fully described. The present study aimed to investigate the circRNA microarray in the DN mice model and then clarify the underlying biological characteristics of circRNAs on the DN physiological and pathological processes.

In the present study, a subset of circRNAs were identified through the circRNA microarray analysis. Heat maps and volcano plots showed a total of 40 circRNAs were differentially expressed, including 18 upregulated circRNAs and 22 downregulated circRNAs. Among these abnormal circRNAs, the present study selected an upregulated circRNA, circRNA_0000491, and investigated the pathological phenotype associated with EMT, one of the known underlying mechanisms of DN. The present study initially assessed the potential effect of circRNA_0000491 on ECM and fibrosis-associated protein expression, then performed loss-of-function experiments through siRNA transfection. The loss-of-function experiments demonstrated that compromised circRNA_0000491 expression significantly suppressed the protein expression levels of Vim, FN and α-SMA, as well as Col. I, III and IV, indicating that circRNA_0000491 participated in the ECM accumulation of the EMT process. This suggested that silencing its expression would be conducive to decrease the synthesis of fibrosis-associated proteins.

Accumulating studies have demonstrated that circRNAs are crucial regulators in the process of the transmission and function of genetic information, usually acting as miRNA sponges. Research on circRNAs in DM is a novel research field and further research into specific circRNA expression on the ECM is still required, despite recent advancements. For example, Wu et al (24) investigated hsa_circ_0005105 expression in osteoarthritis and reported that hsa_circ_0005105 could promote ECM degradation through sponging miR-26a targeting NAMPT. Zhao et al (25) indicated that hsa_circ_0054633 may be a potential biomarker and have a diagnostic capability for pre-diabetes and type 2 DM. In CFs, circRNA_000203 specifically sponges miR-26b-5p and overexpression of circRNA_000203 may eliminate the anti-fibrotic effect of miR-26b-5p in CFs, accompanied by the suppression of collagen type III α 1 chain (Col3a1) and α-SMA (26). Furthermore, emerging evidence has demonstrated that circRNAs may regulate cancer cell proliferation, migration and invasion as miRNA sponge, not only in DN. For instance, Lili and Yue (27) demonstrated that significantly upregulated expression levels of hsa_circ_0007534 are present in breast cancer (BC) and knockdown of hsa_circ_0007534 inhibited BC colony formation, cell proliferation and invasion, as well as strengthening apoptosis in BC cells by acting as a miR-593 sponge to raise mucin 19, oligomeric (MUC19) expression levels. In gastric cancer, the knockdown of hsa_circ_0001368 results in accelerated tumor growth in vivo and may act as a ceRNA to sponge miR-6506-5p and play a tumor-suppressive role (28). Liu et al (29) suggested that circ_0080425 functions as sponge, harboring miR-24-3p, which inhibits cell proliferation and fibrosis in DN by targeting fibroblast growth factor 11. Furthermore, Yao et al (30) demonstrated that circ_0000285 aggravates podocyte injury through sponging miR-654-3p and activating MAPK6 in DN. Taken together, these results provide novel insights into circRNAs and add to the growing amount of evidence that circRNAs can sequester miRNAs.

Mechanistically, in the present study, the interaction between miR-101b and circRNA_0000491 was predicted using bioinformatics analysis, and was confirmed by the luciferase report assay. Thus, circRNA_0000491 may act as an endogenous miR-101b sponge to promote ECM degradation. Additionally, the target genes of miR-101b were predicted using bioinformatics analysis. Subsequently, dual-luciferase reporter assays further confirmed that TGFβRI serves as the target gene of miR-101b. TGF-β1/Smad signaling is critical in the process of EMT. Dysregulation of the signaling pathway can contribute to abnormal ECM deposition, causing extensive kidney fibrosis (31,32). In this pathway, TGF-β1 exerts biological effects through binding to type II β-β receptor and subsequently recruits and activates TGFβRI, then the activated TGFβR1 phosphorylates Smad2/3 (33,34). Previous studies have demonstrated that inhibiting TGFβRI significantly improves various disease, including pulmonary fibrosis (35), hypertensive nephropathy (36) and tubulo-interstitial fibrosis (37), suggesting that inhibiting TGFβRI may be a promising anti-fibrotic therapeutic strategy for DN. These findings are consistent with the current study where it was found that circRNA_0000491 knockdown inhibited TGFβ1, TGFβRI and pSmad3 protein expression levels (34,36).

In conclusion, the high expression levels of circRNA_0000491 in db/db mice and high concentration glucose-induced MCs was negatively correlated with miR-101b expression. Furthermore, the results from the present study indicated that the circRNA_0000491/miR-101b/TGFβRI axis may regulate ECM and fibrosis-associated protein synthesis of DN. Therefore, circRNA_0000491 may be considered as a DN-promoting gene and may represent a novel insight for the treatment of DN.

Funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 81774217 and 81273623), Zhejiang Traditional Chinese Medicine Administration (grant nos. 2017ZKL016 and 2019ZB096) and the Science and Technology Commission of Hangzhou (grant no. 20150733Q42).

Availability of data and materials

The datasets analyzed/generated during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

XM, JWC, DYZ and YBH conceived and designed the present study. XM, KL and LJC performed the experimental procedures. KL, LJC and DZ analyzed the data. XM, JWC and YBH drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Animal Care and Welfare Committee of Zhejiang Chinese Medical University.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.